Cochrane · systematic review · CD009528
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis
Smith, S, Waters, V, Jahnke, N, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings
Population: adults and children with cystic fibrosis and P aeruginosa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 change from start of treatment (L) | no estimate extracted | 2 studies · 68 participants | High |
FEV1 change from start of treatment (% predicted) | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
Time to next exacerbation | no estimate extracted | 1 study · 39 participants | Moderate Downgraded: imprecision |
Adverse events: number of moderate adverse events | RR 0.36 [0.07, 1.77] | 2 studies · 73 participants | Moderate Downgraded: imprecision |
Sputum density: change in P aeruginosa sputum density (log1₀ CFU/g) | no estimate extracted | 2 studies · 70 participants | High |
Quality of life: change in CFQ‐R score from start of treatment | no estimate extracted | 1 study · 38 participants | Moderate Downgraded: imprecision |
Comparison
Population: adults and children with cystic fibrosis and P aeruginosa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV₁ change from start of treatment (L) | no estimate extracted | 2 studies · 68 participants | High |
FEV₁ change from start of treatment (% predicted) | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
Time to next exacerbation | no estimate extracted | 1 study · 39 participants | Moderate Downgraded: imprecision |
Adverse events: number of moderate adverse events. | RR 0.36 [0.07, 1.77] | 2 studies · 73 participants | Moderate Downgraded: imprecision |
Sputum density: change in P aeruginosa sputum density (log₁₀ CFU/g) | no estimate extracted | 2 studies · 70 participants | High |
Quality of life: change in CFQ‐R score from start of treatment | no estimate extracted | 1 study · 38 participants | Moderate Downgraded: imprecision |